Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/12278
Full metadata record
DC FieldValueLanguage
dc.contributor.authorOng, Kevin Ten
dc.contributor.authorVillemagne, Victor Len
dc.contributor.authorBahar-Fuchs, Alexen
dc.contributor.authorLamb, Fionaen
dc.contributor.authorLangdon, Narelleen
dc.contributor.authorCatafau, Ana Men
dc.contributor.authorStephens, Andrew Wen
dc.contributor.authorSeibyl, Johnen
dc.contributor.authorDinkelborg, Ludger Men
dc.contributor.authorReininger, Cornelia Ben
dc.contributor.authorPutz, Barbaraen
dc.contributor.authorRohde, Beateen
dc.contributor.authorMasters, Colin Len
dc.contributor.authorRowe, Christopher Cen
dc.date.accessioned2015-05-16T01:56:23Z
dc.date.available2015-05-16T01:56:23Z
dc.date.issued2014-06-26en
dc.identifier.citationJournal of Neurology, Neurosurgery, and Psychiatry 2014; 86(4): 431-6en
dc.identifier.govdoc24970906en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/12278en
dc.description.abstractWe assessed the clinical utility of β-amyloid (Aβ) imaging with (18)F-florbetaben (FBB) in mild cognitive impairment (MCI) by evaluating its prognostic accuracy for progression to Alzheimer's disease (AD), comparing semiquantitative with visual scan assessment, and exploring the relationships among Aβ, hippocampal volume (HV) and memory over time.45 MCI underwent FBB positron emission tomography, MRI and neuropsychological assessment at baseline and 2 years and clinical follow-up at 4 years. Positive FBB (FBB+), defined by a cortical to cerebellar cortex standardised uptake value ratio (SUVR) ≥ 1.45, was compared with visual assessment by five readers. Amnestic MCI (aMCI) was defined by a composite episodic memory (EM) Z-score of <-1.5.At baseline, 24 (53%) MCI were FBB+. Majority reads agreed with SUVR classification (κ 0.96). In 2 years, 18 (75%) FBB+ progressed to AD compared with 2 (9.5%) FBB-, yielding a predictive accuracy of 83% (95% CI 61% to 94%). Four FBB- developed non-AD dementia. Predictive accuracies of HV (58% (95% CI 42% to 73%)) and aMCI status (73% (95% CI 58% to 81%)) were lower. Combinations did not improve accuracy. By 4 years, 21 (87.5%) FBB+ had AD whereas 5 (24%) FBB- had non-AD dementia yielding a predictive accuracy of 94% (95% CI 74% to 99%). While the strong baseline association between FBB SUVR and EM declined over 2 years, the association between EM and HV became stronger. FBB SUVR increased 2.2%/year in FBB+ with no change in FBB-.(18)F-florbetaben Aβ imaging facilitates accurate detection of prodromal AD. As neurodegeneration progresses, and in contrast with the early stages of the disease, hippocampal atrophy and not Aβ, seems to drive memory decline.NCT01138111.en
dc.language.isoenen
dc.subject.otherALZHEIMER'S DISEASEen
dc.subject.otherAMYLOIDen
dc.subject.otherCOGNITIONen
dc.subject.otherDEMENTIAen
dc.subject.otherMRIen
dc.subject.otherAgeden
dc.subject.otherAlzheimer Disease.metabolism.radionuclide imagingen
dc.subject.otherAmyloid beta-Peptidesen
dc.subject.otherAniline Compounds.diagnostic useen
dc.subject.otherDisease Progressionen
dc.subject.otherFemaleen
dc.subject.otherHippocampus.radionuclide imagingen
dc.subject.otherHumansen
dc.subject.otherMagnetic Resonance Imagingen
dc.subject.otherMaleen
dc.subject.otherMemory Disorders.radionuclide imagingen
dc.subject.otherMild Cognitive Impairment.radionuclide imagingen
dc.subject.otherPositron-Emission Tomographyen
dc.subject.otherProspective Studiesen
dc.subject.otherRadiopharmaceuticals.diagnostic useen
dc.subject.otherStilbenes.diagnostic useen
dc.titleAβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study.en
dc.typeJournal Articleen
dc.identifier.journaltitleJournal of neurology, neurosurgery, and psychiatryen
dc.identifier.affiliationDepartment of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.en
dc.identifier.affiliationDepartment of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia Centre for Research on Aging, Health, and Wellbeing, The Australian National University, Acton, Australian Capital Territory, Australia.en
dc.identifier.affiliationDepartment of Nuclear Medicine, Centre for PET, Austin Health, Heidelberg, Victoria, Australia.en
dc.identifier.affiliationPiramal Imaging GmbH, Berlin, Germany.en
dc.identifier.affiliationMolecular NeuroImaging, L.L.C., New Haven, Connecticut, USA.en
dc.identifier.affiliationBayer Healthcare, Berlin, Germany.en
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia.en
dc.identifier.doi10.1136/jnnp-2014-308094en
dc.description.pages431-6en
dc.relation.urlhttp://www.ncbi.nlm.nih.gov/pubmed/24970906en
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.